Results 91 to 100 of about 5,463 (146)

A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis. [PDF]

Cost Eff Resour Alloc
Du J, Ran H, Zheng Z, Yu X, Feng T.
europepmc   +1 more source

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study. [PDF]

Int J Hematol
Izutsu K, Watanabe M, Toubai T, Tsukamoto T, Maruyama D, Kumode T, Fukuhara N, Ogawa N, Satomi N, Nishimura Y, Honda H, Chyla B, Takizawa J.   +12 more
europepmc   +1 more source

Rituximab resistant pemphigus vulgaris successfully treated with obinutuzumab. [PDF]

JAAD Case Rep
Hiel MAJ, Diercks GFH, Bolling MC, Bremer J, Meijer JM, Horváth B.   +5 more
europepmc   +1 more source

Acute obinutuzumab-induced thrombocytopenia in follicular lymphoma: case report and literature review. [PDF]

Front Oncol
Zhou J, Chen M, Zhang Y, Xu C, Li R.
europepmc   +1 more source

Leukemia Cutis as a Transient Alarm Bell of Disease Progression in a Patient with Chronic Lymphocytic Leukemia under Watchful Waiting. [PDF]

Mediterr J Hematol Infect Dis
Landini S, Corrà A, Sanna A, Di Stefano G, Santi R, Caproni M, Verdelli A.   +6 more
europepmc   +1 more source

Daratumumab combined with anti-CD20 therapy in pediatric and adult refractory idiopathic nephrotic syndrome: single-center experience. [PDF]

Front Immunol
Naciri Bennani H, Sandaye T, Charroyer Q, Etangsale A, Vacher Coponat H, Julien M, Mear V, Dunand O, Di Ascia L.   +8 more
europepmc   +1 more source

First-line treatment for CLL in the era of targeted therapy. [PDF]

Blood Cancer J
Davids MS, Stilgenbauer S, Tam CS.
europepmc   +1 more source

Borrelia afzelii Hepatitis in Patient Treated with Venetoclax and Obinutuzumab, Switzerland. [PDF]

Emerg Infect Dis
Capoferri G, Battegay R, Hamelin B, Keller PM, Mertz KD, Weisser M.   +5 more
europepmc   +1 more source

Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience. [PDF]

Front Immunol
Wu C, Wang Y, Chen S, Lin Y, Du F, Wang X, Chen S, Lu L, Ye S, Ding H, Fu Q.   +10 more
europepmc   +1 more source

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia. [PDF]

Hemasphere
Córdoba R, Stilgenbauer S, Ghia P, Tedeschi A, Roeker L, Rodriguez-Couso M, Mulligan SP, Nabhan SK, Rynne J, López-Fernández T.   +9 more
europepmc   +1 more source